| Patent Number |
Title Of Patent |
Date Issued |
| RE39355 |
Preparation of human IGF via recombinant DNA technology |
October 17, 2006 |
| Human insulin-like growth factor is synthesized in recombinant cell culture by host cells transformed with expression vectors bearing DNA encoding human insulin-like growth factor. |
| 7390887 |
Antibodies against PRO4330 |
June 24, 2008 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7390886 |
PRO9822 antibodies |
June 24, 2008 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7368558 |
PRO357 nucleic acids |
May 6, 2008 |
| The present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides |
| 7309766 |
PRO5774 polypeptides |
December 18, 2007 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7304143 |
PRO1571 antibodies |
December 4, 2007 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7300758 |
Nucleic acid underexpressed in esophageal tumor |
November 27, 2007 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7294705 |
Anti-PRO3580 antibodies |
November 13, 2007 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7282569 |
PRO1508 antibodies |
October 16, 2007 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7268112 |
Use of insulin for the treatment of cartilaginous disorders |
September 11, 2007 |
| The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combin |
| 7193045 |
Polypeptides that induce cell proliferation |
March 20, 2007 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7189805 |
Secreted and transmembrane polypeptides and nucleic acids encoding the same |
March 13, 2007 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7098312 |
Secreted and transmembrane polypeptides and nucleic acids encoding the same |
August 29, 2006 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7084258 |
Antibodies against the PRO862 polypeptides |
August 1, 2006 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7074592 |
Secreted and transmembrane polypeptides nucleic acid encoding |
July 11, 2006 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7034123 |
Anti-PRO1347 antibodies |
April 25, 2006 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 7033825 |
Secreted and transmembrane polypeptides and nucleic acids encoding the same |
April 25, 2006 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 6994988 |
Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
February 7, 2006 |
| DNA isolates coding for tissue factor protein and methods of obtaining such DNA and producing tissue factor protein using recombinant expression systems for use in therapeutic composition for the treatment of coagulation disorders. |
| 6984519 |
Nucleic acids encoding peptides that induce chondrocyte redifferentiation |
January 10, 2006 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invent |
| 6946262 |
Secreted and transmembrane polypeptides and nucleic acids encoding the same |
September 20, 2005 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention |
| 6913919 |
Secreted and transmembrane polypeptides and nucleic acids encoding the same |
July 5, 2005 |
| The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention |
| 6838554 |
Nucleic acids encoding proteins that stimulate the proliferation of t-lymphocytes |
January 4, 2005 |
| The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes |
| 6660256 |
Porcine mpl ligand |
December 9, 2003 |
| Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocyte progenitor cells. Accordingly, these |
| 6656466 |
Human tumor necrosis factor--immunoglobulin(TNFR1-IgG1) chimera composition |
December 2, 2003 |
| The present invention relates to novel process for the preparation of glycoproteins by mammalian cell culture wherein the sialic acid content of the glycoprotein produced is controlled over a broad range of values by manipulating the cell culture environment. The invention provides for |
| 6420518 |
Insulin-like growth factor agonist molecules |
July 16, 2002 |
| Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal. |
| 6372453 |
Neurturin receptor |
April 16, 2002 |
| NTNR.alpha., NTNR.alpha. extracellular domain (ECD), NTNR.alpha. variants, chimeric NTNR.alpha. (e.g., NTNR.alpha. immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including |
| 6342348 |
Neurturin receptor |
January 29, 2002 |
| NTNR.alpha., NTNR.alpha. extracellular domain (ECD), NTNR.alpha. variants, chimeric NTNR.alpha. (e.g., NTNR.alpha. immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including |
| 6218415 |
Inhibitors or bone reabsorption and antagonists of vitronectin receptors |
April 17, 2001 |
| Novel inhibitors of bone reabsorption and antagonists of vitronectin receptorsThe present invention relates to 5-membered ring heterocycles of the formula I, ##STR1##in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as med |
| 6218387 |
Vitronectin receptor anatagonists, their preparation and their use |
April 17, 2001 |
| The present invention relates to compounds of the formula I,in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bo |
| 6214344 |
Hepatocyte growth factor receptor antagonists and uses thereof |
April 10, 2001 |
| Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. Th |
| 6165464 |
Monoclonal antibodies directed to the HER2 receptor |
December 26, 2000 |
| A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor |
| 6124435 |
Carbohydrate-directed cross-linking reagents |
September 26, 2000 |
| The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiol |
| 6066719 |
Antibody fragments |
May 23, 2000 |
| This invention describes the production of bivalent linear F(ab').sub.2 fragments comprising tandem repeats of a heavy chain fragment V.sub.H -C.sub.H 1-V.sub.H -C.sub.H 1 cosecreted with two light chains, so as to form two functional antigen binding sites, wherein both the C-terminus of |
| 6063585 |
TRAF Inhibitors |
May 16, 2000 |
| The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screeni |
| 6060303 |
TRAF inhibitors |
May 9, 2000 |
| The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screen |
| 6046048 |
Apo-2 ligand |
April 4, 2000 |
| A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also |
| 6030831 |
Tie ligand homologues |
February 29, 2000 |
| The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules. |
| 6028055 |
Receptor selective BNP |
February 22, 2000 |
| Compounds related to BNP have reduced binding affinity for the natriuretic peptide receptor-C but possess improved or equivalent affinity to the wild type BNP for natriuretic peptide receptor-A. The BNP related compounds are suitable for use in the treatment or prophylaxis of various pat |
| 6001621 |
Protein tyrosine kinases |
December 14, 1999 |
| The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequ |
| 5945402 |
Human relaxin formulation |
August 31, 1999 |
| A pharmaceutical composition is provided wherein human relaxin is formulated at an acidic pH of about 4 to less than about 7. The composition, useful for effecting parturition and inhibiting premature delivery, includes a buffer capable of maintaining the pH of the composition within |
| 5879910 |
Hepatocyte growth factor protease domain variants |
March 9, 1999 |
| The invention concerns hepatocyte growth factor (HGF) variants that compise an amino acid alteration at a site within the protease domain of HGF and retaining substantially full receptor binding affinity of the corresponding wild-type HGF. |
| 5874543 |
Antibodies to PF4A receptor |
February 23, 1999 |
| cDNAs encoding a class of receptors, including the IL-8 receptors, have been identified in human tissue. Recombinantly produced PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. The antibodies are advantageous |
| 5869612 |
Tumor necrosis factor receptor-associated factors |
February 9, 1999 |
| The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities. |
| 5849687 |
Acid-labile subunit als of insulin-like growth factor binding proteincomplex |
December 15, 1998 |
| An acid-labile protein is described that, when incubated with the 53-Kd acid-stable protein occupied by IGF, converts it to a high molecular weight complex, corresponding to the in vivo form of IGF. This protein is called the acid-labile subunit (ALS) of IGF binding protein complex and i |
| 5849585 |
Isolating and culturing Schwann cells |
December 15, 1998 |
| A method for enhancing the survival and/or proliferation of Schwann cells (especially human Schwann cells) in cell culture is disclosed which involves culturing the cells in serum free culture medium comprising gas6 and other mitogenic agents, such as heregulin and forskolin. The culturi |
| 5849533 |
Method for making unclipped HIV envelope protein |
December 15, 1998 |
| Methods for making unclipped HIV env proteins are provided. According to the methods, a genetically engineered cell line comprising an nucleic acid sequence encoding an HIV env protein is cultured to produce unclipped HIV env protein, which is recovered from the cell culture. |
| 5840523 |
Methods and compositions for secretion of heterologous polypeptides |
November 24, 1998 |
| The instant invention discloses the unexpected result that mutant signal sequences with reduced translational strength provided essentially complete processing and high levels of expression of a polypeptide of interest as compared to wild type signal sequences, and that many mammalia |
| 5821333 |
Method for making heteromultimeric polypeptides |
October 13, 1998 |
| The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves intro |
| 5759775 |
Methods for detecting nucleic acids encoding AL--1 neurotrophic factor |
June 2, 1998 |
| Provided are nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders. The present invention provides methods to preferentially detect |
| 5702938 |
Human tissue plasminogen activator |
December 30, 1997 |
| Human tissue plasminogen activator (t-PA) is produced in useful quantities using recombinant DNA techniques. The invention disclosed thus enables the production of t-PA free of contaminants with which it is ordinarily associated in its native cellular environment. Methods, expression |
